REGENXBIO said it continues developing investigational gene therapies for retinal diseases and highlighted its vision-health pipeline during Blindness Awareness Month. No new trial, regulatory or commercial milestones were announced.
published
REGENXBIO said it continues developing investigational gene therapies for retinal diseases and highlighted its vision-health pipeline during Blindness Awareness Month. No new trial, regulatory or commercial milestones were announced.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.